Late cytomegalovirus disease following liver transplantation

Transplant International

Volumn 16, Issue 12, 2003, Pages 861-865

  Shibolet, Oren ^a   Ilan, Yaron ^a   Kalish, Yosef ^a   Safadi, Rifaat ^a   Ashur, Yaffa ^a   Eid, Ahmed ^a   Shouval, Daniel ^a   Wolf, Dana ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cytomegalovirus; Late infection; Liver transplantation

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; GANCICLOVIR;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; GRAFT REJECTION; HUMAN; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT INFECTION; RETINITIS; RISK FACTOR; SEPSIS; TREATMENT OUTCOME; VIRUS PNEUMONIA;

EID: 0347518998     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00147-003-0643-x     Document Type: Article

References (25)

1. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996; 22:537.
2. Tolkoff-Rubin NE, Rubin RH. Viral infections in organ transplantation. Transplant Proc 1998; 30:2060.
3. Snydman DR. Infection in solid organ transplantation. Transpl Infect Dis 1999; 1:21.
4. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10:86.
5. Pass RF. Cytomegalovirus. In: Knipe DM, Howlely PM, eds. Field virology, 4th edn., Philadelphia: Lippincott Williams & Wilkins, 2001: 2675.
6. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplantation recipients. Clin Infect Dis 1996; 23:468.
7. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261:3607.
8. Portela D, Patel R, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 17:1014.
9. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176:1484.
10. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate moftil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplat 2000; 15:711.
11. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340:1462.
12. Gane E, Saliba F, Valdecasas GJ. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350: 1729.
13. Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001; 32:596.
14. Razonable RR, Rivero A, Rodriguez A. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184:1461.
15. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001; 33:E62.
16. Boeckh M, Woogerd PM, Stevens-Ayers T, Ray CG, Bowden RA. Factors influencing detection of quantitative cytomegalovirus antigenemia. J Clin Microbiol 1994; 32:832.
17. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094.
18. Fietze E, Prosch S, Reinke P, et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994; 58:675.
19. Docke WD, Prosch S, Fietze E, et al. Cytomegalovirus reactivation and tumour necrosis factor. Lancet 1994; 343: 268.
20. Adler SP. Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med 1989; 321:1290.
21. Pass RF, Hutto C, Lyon MD, Cloud G. Increased rate of cytomegalovirus infection among day care center workers. Pediatr Infect Dis J 1990; 9:465.
22. Kleinman D, Sarov I, Insler V. Reactivation of cytomegalovirus in endometrial cells by estradiol. Gynecol Obstet Invest 1986; 21: 136.
23. Koment RW. Lytic cytomegalovirus replication and the hormones of human pregnancy. J Med Virol 1985; 15:149.
24. Chong KT, Mims CA. Effects of pregnant mouse serum and pregnancy hormones on the replication in vitro of murine cytomegalovirus. Arch Virol 1984; 82:223.
25. Machado CM, Menezes RX, Macedo MC. Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant 2001; 28:1053.